Empery Asset Management LP Purchases New Shares in Talphera, Inc. $TLPH

Empery Asset Management LP purchased a new stake in shares of Talphera, Inc. (NASDAQ:TLPH) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 1,333,497 shares of the company’s stock, valued at approximately $1,520,000. Talphera accounts for approximately 1.3% of Empery Asset Management LP’s portfolio, making the stock its 11th largest position.

Other hedge funds also recently made changes to their positions in the company. Group One Trading LLC boosted its position in shares of Talphera by 3,224.0% during the third quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after purchasing an additional 29,500 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Talphera during the third quarter valued at approximately $29,000. Dauntless Investment Group LLC bought a new stake in shares of Talphera during the third quarter valued at approximately $89,000. Geode Capital Management LLC boosted its position in shares of Talphera by 107.0% during the fourth quarter. Geode Capital Management LLC now owns 342,987 shares of the company’s stock valued at $391,000 after purchasing an additional 177,294 shares in the last quarter. Finally, Nantahala Capital Management LLC boosted its position in shares of Talphera by 75.3% during the third quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock valued at $3,120,000 after purchasing an additional 1,500,000 shares in the last quarter. 37.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Talphera in a research report on Monday, April 20th. Zacks Research upgraded Talphera to a “hold” rating in a research report on Monday. Westpark Capital assumed coverage on Talphera in a research report on Thursday, April 30th. They set a “buy” rating and a $3.00 price target on the stock. Finally, HC Wainwright initiated coverage on Talphera in a research report on Friday, June 5th. They set a “buy” rating and a $3.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $3.00.

Talphera Trading Down 0.9%

Talphera stock opened at $0.81 on Thursday. The business’s fifty day simple moving average is $0.81 and its two-hundred day simple moving average is $0.94. Talphera, Inc. has a 12 month low of $0.38 and a 12 month high of $1.57. The company has a market capitalization of $41.95 million, a price-to-earnings ratio of -2.61 and a beta of 0.76.

Talphera (NASDAQ:TLPH) last released its earnings results on Wednesday, May 13th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. On average, equities research analysts predict that Talphera, Inc. will post -0.26 EPS for the current year.

Insider Buying and Selling

In related news, CEO Vincent J. Angotti bought 213,310 shares of the company’s stock in a transaction on Friday, March 13th. The shares were acquired at an average cost of $0.59 per share, with a total value of $125,852.90. Following the completion of the acquisition, the chief executive officer owned 800,705 shares of the company’s stock, valued at $472,415.95. The trade was a 36.31% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 3.50% of the company’s stock.

Talphera Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.